Overview

A Placebo Controlled Trial of the Dopamine D-2 Receptor Agonist Ropinirole in Treatment of 60 Patients With Refractory Bipolar Depression.

Status:
Unknown status

Trial end date:
1969-12-31

Target enrollment:

Participant gender:

Summary

We hypothesize that depressed patients who have not responded to their current antidepressant medication will respond to the addition of ropinirole to their current regimen at a rate better than placebo.

Phase:

Phase 4

Details

Lead Sponsor:

Sheba Medical Center

Collaborator:

Jerusalem Mental Health Center

Treatments:

Dopamine
Dopamine Agents
Ropinirole